

Applicants: Robert H. DeBellis et al.  
Serial No.: 09/828, 413  
Filed: April 6, 2001  
Page 2

In the claims:

Please amend claim 1 under the provisions of revised 37 C.F.R. §1.121 as follows.

1. (currently amended) A method of treating sickle cell disease in a subject ~~afflicted with sickle cell disease~~ which comprises administering to the subject an amount of an antiviral agent, other than hydroxyurea, effective to inhibit sickling of a cell in the subject, so as to thereby treat sickle cell disease in the subject ~~afflicted with sickle cell disease~~.
2. - 9. (withdrawn)
10. (previously presented) The method of claim 1, wherein the cell is an erythrocyte cell.
11. - 12. (withdrawn)
13. (previously presented) The method of claim 1, wherein the antiviral agent is a purine analog.
14. (original) The purine analog of claim 13, wherein the purine analog is a guanosine analog.
15. (original) The guanosine analog of claim 14, wherein the guanosine analog is acyclovir.

Applicants: Robert H. DeBellis et al.  
Serial No.: 09/828,413  
Filed: April 6, 2001  
Page 3

16. (original) The guanosine analog of claim 14, wherein the guanosine analog is valacyclovir.
17. (previously amended) The method of claim 1, wherein the sickle cell disease is selected from the group consisting of sickle cell anemia, sickle  $\beta$ -thalassemia, sickle cell-hemoglobin C disease and any other sickle hemoglobinopathy in which hemoglobin S interacts with a hemoglobin other than hemoglobin S.
18. (previously amended) The method of claim 1, wherein the subject is a mouse, rat, dog, guinea pig, ferret, rabbit, primate, or human being.
19. (previously amended) The method of claim 1, wherein the antiviral agent is administered to a subject via intralesional, intramuscular, subcutaneous, intravenous, intraperitoneal, liposome mediated, transmucosal, intestinal, topical, nasal, oral, anal, ocular or otic delivery.